Known targets — ChEMBL curated mechanism
KCNA5KCND3KCNH2KCNJ3KCNJ5SCN5A
The experimentally established mechanism targets of Vernakalant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 known ✓ | P22460 | 6/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 6/20 | 1.00 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 1.00 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vernakalant SCHEMBL1762185 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL439144 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL441544 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL6276115 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL4615829 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL3338844 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL439679 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL439706 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL443797 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL442387 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868598-B1 | A NEW DOSING REGIMEN FOR ION CHANNEL MODULATING COMPOUNDS FOR TREATING ACUTE ATRIAL FIBRILLATION IN A HUMAN | CARDIOME PHARMA CORP (CA) | 2014-04-23 | — | — | EP | disclosed |
| US-8263638-B2 | e.g. 2-(hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)cyclohexane; sodium channel blocking agent; arrythmias (e.g. atrial fibrillation, atrial flutter, early after depolarizations and prolongation of QT interval) | CARDIOME PHARMA CORP. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-8188140-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. | 2012-05-29 | — | — | US | disclosed |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2011-05-19 | — | — | US | disclosed |
| US-7820712-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-7674820-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2010-03-09 | — | — | US | disclosed |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090041841-A1 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS | CARDIOME PHARMA CORP. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2008-08-07 | — | — | US | disclosed |
| US-20080171785-A1 | Dosing Regimens For Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-7345086-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-20060135536-A9 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2006-06-22 | — | — | US | disclosed |
| WO-2005097869-A1 | POLYMERS COMPRISING ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-10-20 | — | — | WO | disclosed |
| US-20050070552-A1 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2005-03-31 | — | — | US | disclosed |
| US-20050026993-A1 | Uses of ion channel modulating compounds | CORREVIO CANADA CORP. (CA) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041841-A1 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS | KCNN3, KCNN2, KCNN1 | KCNA5 78/4885SCN5A 59/4885KCNH2 17/4885 |
| US-20050070552-A1 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KCNA5 45/4885SCN5A 71/4885KCNH2 13/4885 |
| US-20080171785-A1 | Dosing Regimens For Ion Channel Modulating Compounds | KCNN3, KCNN2, KCNN1 | KCNA5 59/4885SCN5A 39/4885KCNH2 21/4885 |
| US-20050026993-A1 | Uses of ion channel modulating compounds | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885KCNH2 16/4885 |
| US-20060135536-A9 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KCNA5 45/4885SCN5A 71/4885KCNH2 13/4885 |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNN2 | KCNA5 31/4885SCN5A 59/4885KCNH2 11/4885 |
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885KCNH2 16/4885 |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885KCNH2 16/4885 |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNJ2 | KCNA5 34/4885SCN5A 64/4885KCNH2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.